Form 4: Foghorn Therapeutics Director Acquires 25,000 Stock Options
Insider Transaction Report
Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc., has acquired 25,000 stock options with an exercise price of $4.79 per share, as disclosed in a recent SEC Form 4 filing.
Summary
- Thomas J. Lynch Jr., a Director of Foghorn Therapeutics Inc. (FHTX), reported the acquisition of derivative securities.
- The transaction involved the acquisition of 25,000 stock options, granting the right to buy common stock.
- The exercise price for these options is $4.79 per share.
- The transaction date for this acquisition was June 17, 2025.
- These stock options will become exercisable on June 17, 2026, and are set to expire on June 16, 2035.
- Following this reported transaction, Mr. Lynch directly beneficially owns 25,000 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The acquisition of stock options by a director can be interpreted as a positive signal of confidence in the company's future prospects, although it is a routine insider transaction disclosure and not indicative of major operational or financial news.
Positives
- The acquisition of stock options by a director can be interpreted as a positive signal of management's confidence in the company's future performance and stock value.
Future Outlook
The document, an SEC Form 4, is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This SEC Form 4 filing reports an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry trends or competitive analysis.
Related Party Transactions
- Thomas J. Lynch Jr., a Director of Foghorn Therapeutics Inc., acquired 25,000 stock options from the company at an exercise price of $4.79 per share.
Stakeholder Impact
- Shareholders may view the director's acquisition of stock options as a positive indicator of alignment between management and shareholder interests, suggesting confidence in the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 06/17/2025 | Date of earliest transaction and signature date for the filing. |
| 06/17/2026 | Date when the acquired stock options become exercisable. |
| 06/16/2035 | Expiration date of the acquired stock options. |
Keywords
Foghorn Therapeutics, FHTX, Stock Option, Insider Transaction, Form 4, Director, Equity, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.